<DOC>
	<DOCNO>NCT01714544</DOCNO>
	<brief_summary>The purpose study determine whether Cloderm Cream effective topical treatment moderate psoriasis 28 day .</brief_summary>
	<brief_title>Study Efficacy ClodermÂ® Cream Treatment Moderate Plaque Psoriasis</brief_title>
	<detailed_description>The objective study estimate efficacy Cloderm Cream topical treatment moderate plaque psoriasis 28 day use current standard evaluation .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clocortolone pivalate</mesh_term>
	<mesh_term>Clocortolone</mesh_term>
	<mesh_term>Fluocortolone</mesh_term>
	<criteria>1 . Subject understands study procedure agree participate give write informed consent . 2 . Subjects must least 18 year age . 3 . Subjects must present clinical diagnosis stable ( least 3 month ) plaquetype psoriasis . 4 . Subjects psoriasis involve 2 20 % BSA , include face , scalp intertriginous area . 5 . Subjects must IGA Grade 3 Baseline Visit . 6 . Female subject childbearing potential must negative urine pregnancy test result Baseline ( Visit 2 ) ( test sensitivity least 25mIU/ml human chorionic gonadotropin ) practice reliable method contraception remain sexually inactive throughout study . All woman childbearing potential must willing undergo urine pregnancy test Visit 2 ( Day 0 ) , Visit 4 ( Day 14 ) , Visit 5 ( Day 28 ) . 7 . Subjects must good general health determine investigator support medical history normal clinically significant abnormal vital sign ( blood pressure pulse ) . 1 . Current diagnosis unstable form psoriasis include guttate , erythrodermic , exfoliative pustular psoriasis . 2 . Other inflammatory skin disease may confound evaluation plaque psoriasis ( e.g. , atopic dermatitis , contact dermatitis , tinea corporis ) . 3 . Presence pigmentation , extensive scarring , pigment lesion sunburn could interfere rating efficacy parameter . 4 . History psoriasis unresponsive topical treatment . 5 . History organ transplant require immunosuppression , HIV , immunocompromised state . 6 . Use within 180 day prior Baseline Visit biologic treatment psoriasis ( e.g. , infliximab , adalimumab , etanercept , ustekinumab , alefacept ) . 7 . Have receive treatment type cancer within 5 year Baseline Visit except nonmelanoma skin cancer cervical cancer ( situ ) allow within 1 year Baseline Visit . 8 . Use within 60 day prior Baseline Visit : 1 ) immunosuppressive drug ( e.g. , tacrolimus , pimecrolimus ) , 2 ) systemic antipsoriatic treatment ( e.g. , methotrexate , cyclosporine , hydroxyurea ) 3 ) oral retinoids ( e.g. , acitretin , isotretinoin ) . 9 . Use within 30 day prior Baseline Visit : 1 ) systemic steroid , 2 ) PUVA therapy , 3 ) systemic antiinflammatory agent ( e.g. , mycophenolate mofetil , sulfasalazine , 6thioguanine ) , 4 ) UVB therapy . Note : Inhaled , intraocular intranasal steroid allow . 10 . Use within 14 day prior Baseline Visit : 1 ) topical antipsoriatic drug ( e.g. , salicylic acid , anthralin , coal tar , calcipotriene ) , 2 ) topical retinoids ( e.g. , tazarotene , tretinoin ) 3 ) topical corticosteroid . 11 . Subjects know hypersensitivity clocortolone pivalate component Cloderm Cream . 12 . Subjects participate study investigational drug 60 day prior Baseline Visit . 13 . Subjects unable comply study requirement . 14 . Female subject pregnant ( plan become pregnant ) breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>